PreprintCited by 105Circular RNAs in diseasesCancer-related molecular mechanisms researchRNA Research and Splicing

The circular RNome of primary breast cancer

Open access
Smid, Marcel, Wilting, Saskia M., Uhr, Katharina, Rodríguez-González, F. Germán, de Weerd, Vanja, Prager-Van der Smissen, Wendy J.C., van der Vlugt-Daane, Michelle, van Galen, Anne +33 more·2019·Genome Research

Abstract

Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely on unmapped reads or known splice junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of the circRNAs that match exon boundaries of the same gene, 668 showed a poor or even negative (R < 0.2) correlation with the expression level of the linear gene. In silico analysis showed only a minority (8.5%) of circRNAs could be explained by known splicing events. Both these observations suggest that specific regulatory processes for circRNAs exist. We confirmed the presence of circRNAs of CNOT2, CREBBP, and RERE in an independent pool of primary breast cancers. We identified circRNA profiles associated with subgroups of breast cancers and with biological and clinical features, such as amount of tumor lymphocytic infiltrate and proliferation index. siRNA-mediated knockdown of circCNOT2 was shown to significantly reduce viability of the breast cancer cell lines MCF-7 and BT-474, further underlining the biological relevance of circRNAs. Furthermore, we found that circular, and not linear, CNOT2 levels are predictive for progression-free survival time to aromatase inhibitor (AI) therapy in advanced breast cancer patients, and found that circCNOT2 is detectable in cell-free RNA from plasma. We showed that circRNAs are abundantly present, show characteristics of being specifically regulated, are associated with clinical and biological properties, and thus are relevant in breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gr.238121.118

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cancer cells have probably exploited mechanisms of RNA Pol II speed regulation given the variety of circular and read-through RNAs whose expression is affected during cancer progression.

    “Cancer cells have probably exploited such mechanisms given the variety of circular and read‐through RNAs whose expression is affected during cancer progression (Grosso et al, 2015; Smid et al, 2019).”

    From RNA polymerase II speed: a key player in controlling and adapting transcriptome composition (2021) · cites this paper as Smid et al, 2019

    The Abstract (page unavailable) reports diverse circular RNAs in breast cancer, with expression profiles associated with tumor subgroups and clinical features. It does not establish that cancer cells exploit RNA Pol II speed regulation or report changes in read-through RNA expression during cancer progression; its progression finding concerns survival after therapy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Smid, M., Wilting, S. M., Uhr, K., Rodríguez-González, F. G., de Weerd, V., Prager-Van der Smissen, W. J. C., van der Vlugt-Daane, M., van Galen, A., Nik-Zainal, S., Butler, A., Martin, S., Davies, H. R., Staaf, J., van de Vijver, M. J., Richardson, A. L., MacGrogan, G., Salgado, R., van den Eynden, G. G. G. M., Purdie, C. A., Thompson, A. M., Caldas, C., Span, P. N., Sweep, F. C. G. J., Simpson, P. T., Lakhani, S. R., Van Laere, S., Desmedt, C., Paradiso, A., Eyfjord, J., Broeks, A., Vincent-Salomon, A., Futreal, A. P., Knappskog, S., King, T., Viari, A., Børresen-Dale, A.-L., Stunnenberg, H. G., Stratton, M., Foekens, J. A., Sieuwerts, A. M., & Martens, J. W. M.
Affiliations
  • Erasmus MC (NL)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Wellcome Sanger Institute (GB)
  • Lund University (SE)
  • Brigham and Women's Hospital (US)
  • Institut Bergonié (FR)
  • Université Libre de Bruxelles (BE)
  • Ninewells Hospital (GB)
  • University of Cambridge (GB)
  • Radboud University Medical Center (NL)
  • The University of Queensland (AU)
  • Istituto Tumori Bari (IT)
  • University of Iceland (IS)
  • The Netherlands Cancer Institute (NL)
  • The University of Texas MD Anderson Cancer Center (US)
  • Haukeland University Hospital (NO)
  • Memorial Sloan Kettering Cancer Center (US)
  • Institut national de recherche en sciences et technologies du numérique (FR)
  • Radboud University Nijmegen (NL)
Venue
Genome Research
Published
2019-01-28
Volume
29
Issue
3
Pages
356-366
ISSN
  • 1088-9051 (ISSN-L)
  • 1549-5469
OpenAlex
W6963131477
Cited by
105
References
45
Citations by year
2026: 4 · 2025: 9 · 2024: 6 · 2023: 17 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 9
Type
posted content
Language
en
Open access
Locations
  • Genome Research (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Lirias (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Opin vísindi (Opin vísindi) (submittedVersion, cc-by-nc)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • Apollo
Funders
  • ICGC Breast Cancer Working group by the Breast Cancer Somatic Genetics Study
  • European Community's Seventh Framework Programme (FP7/2010-2014, 242006)
  • Wellcome Trust (077012/Z/05/Z)
  • BASIS
  • ERC (ERC-2012-AdG-322737, ERC-2017-PoC-767854)
  • Daniel den Hoed Foundation
  • Wellcome Beit Fellow
  • Wellcome Trust Intermediate Fellowship (WT100183MA)
  • Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer (NIH/NCI 5 P50 CA168504-02)
  • Cancer Genomics Netherlands
  • Netherlands Organization of Scientific research (EU-FP7-DDR)
  • Breast Cancer Research Foundation
  • The Icelandic Centre for Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Circular RNAs in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
circular RNA, primary breast cancer, circRNA identification, circRNA expression profiling, breast cancer subtypes, cell proliferation, siRNA knockdown, cell viability, aromatase inhibitor therapy, progression-free survival, cell-free RNA, plasma biomarkers, advanced breast cancer
MeSH terms
RNA, Circular, Breast Neoplasms, Carrier Proteins, Female, Humans, Lymphatic Metastasis, Repressor Proteins, RNA, Biomarkers, Tumor, CREB-Binding Protein, Transcriptome, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review